Our research at AIDS 2024 and the International Workshop on Pediatrics & HIV
17 Jul 2024
Researchers from the MRC Clinical Trials Unit at UCL and our partner institutions will showcase their latest HIV research at AIDS 2024, the 25th International AIDS Conference. This year’s conference takes place from Monday 22 to Friday 26 July in Munich, Germany and virtually.
Our HIV studies will feature in talks and posters at the main AIDS 2024 conference, as well as the pre-conference International Workshop on HIV & Pediatrics 2024, running from Friday 19 to Saturday 20 July in Munich.
Thousands are expected to attend AIDS 2024, including people living with HIV and researchers working on HIV, to share knowledge, best practices and lessons learnt from the HIV response and other public health threats. Researchers will present the latest evidence from basic science through to clinical research, epidemiology and social science, as well as implementation science surrounding novel approaches to treatment and prevention. This year's AIDS 2024 conference is based around the theme 'Put people first!', which encourages thinking of solutions from the perspectives of those most effective.
The International Workshop on HIV & Pediatrics focuses specifically on HIV in infants, children and adolescents. An estimated 1.68 million children under 15 years old are living with HIV and only 54% are receiving antiretroviral therapy. Furthermore, adolescents are one of the most rapidly growing populations with HIV. The workshop aims to stimulate research to improve prevention and treatment of paediatric HIV.
Details of MRC CTU at UCL posters and presentations taking place at the conference and pre-conference workshops are shown below. All times are CEST.
International Workshop on HIV & Pediatrics:
| Date and time (CEST) | Session | Title | Presenter |
| Friday 19 July, 08:45 AM | Session 1 – Global update on pediatric HIV |
The epidemiology of HIV and hepatitis in pregnant women, children, and adolescents in the European region |
Ali Judd |
| Friday 19 July, 11:30 AM | Session 2 – Pediatric care and treatment |
Viral failure in children and adolescents living with HIV on dolutegravir (DTG) in Europe and Thailand |
Karen Scott |
| Friday 19 July, 03:00 PM | Session 3 – Comorbidities/infections |
DTG-based ART is not associated with excessive weight gain in children: 192 weeks follow-up in the ODYSSEY randomised trial |
Anna Turkova |
| Saturday 20 July, 10:40 AM | Session 4 – Prevention of new pediatric HIV |
Debate: No infant antiretroviral prophylaxis for infants born to mothers with HIV who are virally suppressed |
Chaired by Diana Gibb |
| Saturday 20 July, 11:30 AM | Session 4 – Prevention of new pediatric HIV |
Short oral poster presentation: Genotypic resistance to integrase inhibitors, protease inhibitors and tenofovir alafenamide is uncommon in children with virological rebound in the CHAPAS-4 randomised trial of second-line antiretroviral therapy for children with HIV in Africa |
Cissy Kityo |
| Saturday 20 July, 05:35 PM | Session 5 – Adolescents and young adults | Effectiveness and safety of tenofovir alafenamide fumarate (TAF)-based therapy compared to tenofovir disoproxil fumarate (TDF)- and abacavir (ABC)-based therapy in children and adolescents living with HIV (CALHIV) in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) | Lizzie Chappell |
Posters:
|
Title |
Presenter |
|
Effectiveness and safety of dolutegravir in children and adolescents living with HIV in Europe and Thailand |
John O’Rourke |
|
Changes in body mass index in children and adolescents living with HIV in Europe and Thailand before and after starting dolutegravir and compared to protease inhibitors |
Siobhan Crichton |
|
Weight gain on tenofovir alafenamide fumarate (TAF)–based therapy compared to tenofovir disoproxil fumarate (TDF)- and abacavir (ABC)-based therapy in children and adolescents living with HIV (CALHIV) in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) |
Siobhan Crichton |
|
Genotypic resistance to integrase inhibitors, protease inhibitors and tenofovir alafenamide is uncommon in children with virological rebound in the CHAPAS-4 randomised trial of second line antiretroviral therapy for children with HIV in Africa |
Cissy Kityo |
International AIDS Conference 2024:
| Date and time (CEST) | Session | Title | Presenter |
| Tuesday 23 July, 08:33 AM | Plenary session - Putting people first: The way forward (PL01) | Do not forget the children: Pioneering progress in paediatric HIV care | Anna Turkova |
| Tuesday 23 July, 05:05 PM | HIV and STI prevention: Understanding preferences and perceptions | Final vaccine efficacy results from PrEPVacc: A phase IIb HIV prophylactic vaccine trial of two active regimens each compared to placebo | Eugene Ruzagira |
| Friday 26 July, 01:30 PM | An INSTIgrated tale |
Increasing second-line antiretroviral therapy options for children with HIV in Africa: week-96 efficacy and safety results of the CHAPAS-4 randomised trial |
Karen Scott |
Posters
|
Title |
Presenter |
|
Effectiveness and safety of tenofovir alafenamide fumarate (TAF) –based therapy in children and young people living with HIV (CYP) in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) |
Jeannie Collins |
|
Changes in body mass index in children and adolescents in Europe and Thailand before and after starting dolutegravir and compared to protease inhibitors using propensity scoring analysis |
Jeannie Collins |
|
Comparative analysis of antibody responses to CN54gp140 and AIDSVAX B/E in the PrEPVacc Trial |
Jennifer Serwanga |
|
HIV incidence remains relatively high among women despite the availability of effective interventions |
Sylvia Kusemererwa |
|
Disclosing participation in an HIV vaccine and PrEP trial in southwestern Uganda – the effect on participant engagement |
Sarah Nakamanya |
|
HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial: a qualitative longitudinal study, South Africa |
Rujeko Samanthia Chimukuche |
|
Knowledge and experiences of participating in an HIV vaccine efficacy trial with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda |
Rachel Kawuma |
|
“I am not sick now, why should I swallow daily pills”: non-uptake of and adherence to daily oral pre-exposure prophylaxis among adults at high risk of HIV in Masaka, Uganda |
Rachel Kawuma |
|
Final vaccine efficacy results from PrEPVacc: A phase IIb HIV prophylactic vaccine trial of two active regimens each compared to placebo |
Eugene Ruzagira |
Further information: